

1 **Diagnosis and analysis of unexplained cases of childhood**  
2 **encephalitis in Australia using metagenomic next-**  
3 **generation sequencing**

4  
5 **Ci-Xiu Li<sup>1,2†</sup>, Rebecca Burrell<sup>2,3†</sup>, Russell C Dale<sup>4</sup>, Alison Kesson<sup>2,3</sup>,**  
6 **Christopher C Blyth<sup>5,6,7</sup>, Julia E Clark<sup>8,9</sup>, Nigel Crawford<sup>10</sup>, Cheryl A.**  
7 **Jones<sup>2,3,11†</sup>, Philip N. Britton<sup>2,3,11†</sup>, Edward C. Holmes<sup>1,2†\*</sup> on behalf of the**  
8 **Australian Childhood Encephalitis study investigators.**

9  
10 <sup>1</sup>School of Life and Environmental Sciences and School of Medical Sciences, The University  
11 of Sydney, NSW, Australia.

12 <sup>2</sup>Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney Medical School, The  
13 University of Sydney, NSW, Australia.

14 <sup>3</sup>The Children's Hospital at Westmead, Westmead, NSW, Australia.

15 <sup>4</sup>Kids Neuroscience Centre, Children's Hospital at Westmead Clinical School, Faculty of  
16 Medicine, University of Sydney, NSW, Australia.

17 <sup>5</sup>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute and School  
18 of Medicine, University of Western Australia, Nedlands, WA, Australia.

19 <sup>6</sup>Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA, Australia.

20 <sup>7</sup>Department of Microbiology, PathWest Laboratory Medicine WA, QEII Medical Centre,  
21 Nedlands, WA, Australia.

22 <sup>8</sup>Infection Management, Queensland Children's Hospital, Brisbane, QLD, Australia.

23 <sup>9</sup>School of Clinical Medicine, Childrens Health Queensland Clinical Unit, University of  
24 Queensland, QLD, Australia.

25 <sup>10</sup>Murdoch Children's Research Institute, Royal Children's Hospital Flemington Road,  
26 Parkville, VIC 3052 Australia.

27 <sup>11</sup>Kids Research, Sydney Children's Hospitals Network (Westmead), Westmead, NSW,  
28 Australia,

29

30 \*Correspondence to:

31 Prof. Edward C. Holmes

32 Marie Bashir Institute for Infectious Diseases & Biosecurity,

33 School of Life & Environmental Sciences and School of Medical Sciences

34 The University of Sydney | Sydney | NSW | 2006 | Australia

35 T +61 2 9351 5591; E [edward.holmes@sydney.edu.au](mailto:edward.holmes@sydney.edu.au)

36

37 †Contributed equally to the paper.

## 38 **Abstract**

39 Encephalitis is most often caused by a variety of infectious agents, the identity of which is  
40 commonly determined through diagnostic tests utilising cerebrospinal fluid (CSF). Immune-  
41 mediated disorders are also a differential in encephalitis cases. We investigated the clinical  
42 characteristics and potential aetiological agents of unexplained encephalitis through  
43 metagenomic next-generation sequencing of residual clinical samples of multiple tissue types  
44 and independent clinical review. A total of 43 specimens, from both sterile and non-sterile  
45 sites, were collected from 18 encephalitis cases with no cause identified by the Australian  
46 Childhood Encephalitis study. Samples were subjected to total RNA sequencing to determine  
47 the presence and abundance of potential pathogens, to reveal mixed infections, pathogen  
48 genotypes, and epidemiological origins, and to describe the possible aetiologies of  
49 unexplained encephalitis. From this, we identified five RNA and two DNA viruses associated  
50 with human infection from both non-sterile (nasopharyngeal aspirates, nose/throat swabs,  
51 urine, stool rectal swab) and sterile (cerebrospinal fluid, blood) sites. These comprised two  
52 human rhinoviruses, two human seasonal coronaviruses, two polyomaviruses and one  
53 picobirnavirus. With the exception of picobirnavirus all have been previously associated with  
54 respiratory disease. Human rhinovirus and seasonal coronaviruses may be responsible for five  
55 of the encephalitis cases reported here. Immune-mediated encephalitis was considered  
56 clinically likely in six cases and RNA sequencing did not identify a possible pathogen in  
57 these cases. The aetiology remained unknown in nine cases. Our study emphasises the  
58 importance of respiratory viruses in the aetiology of unexplained child encephalitis and

59 suggests that the routine inclusion of non-CNS sampling in encephalitis clinical  
60 guidelines/protocols could improve the diagnostic yield.

61

## 62 **Author Summary**

63 Encephalitis is caused by both infectious agents and auto-immune disorders. However, the  
64 aetiological agents, including viruses, remain unknown in around half the cases of  
65 encephalitis in many cohorts. Importantly, diagnostic tests are usually based on the analysis  
66 of cerebrospinal fluid which may limit their utility. We used a combination of meta-  
67 transcriptomic sequencing and independent clinical review to identify the potential causative  
68 pathogens in cases of unexplained childhood encephalitis. Accordingly, we identified seven  
69 viruses associated with both sterile and non-sterile sampling sites. Human rhinovirus and  
70 seasonal coronaviruses were considered as most likely responsible for five of the 18  
71 encephalitis cases studied, while immune-mediated encephalitis was considered the cause in  
72 six cases, and we were unable to determine the aetiology in nine cases. Overall, we  
73 demonstrate the role of respiratory viruses as a cause of unexplained encephalitis and that  
74 sampling sites other than cerebrospinal fluid is of diagnostic value.

75

76 **Keywords.** Unexplained encephalitis, meta-transcriptomics, non-sterile sites, virus, pathogen  
77 discovery

## 78 **Introduction**

79 Encephalitis, defined as inflammation of the brain tissue, is caused by a broad range of  
80 infectious agents, including bacteria, viruses, fungi and parasites, as well as a number of auto-  
81 immune disorders [1, 2]. However, in 40% to 60% of cases in many cohorts the aetiological  
82 agents remain unknown [3, 4]. Investigation is challenging because clinical presentation may  
83 be atypical and the differential diagnosis may include unusual and opportunistic pathogens –  
84 especially if the patient is immunosuppressed - or a non-infective cause. The conventional  
85 means of infectious encephalitis diagnosis are specific PCR assays on central nervous system  
86 samples including cerebrospinal fluid (CSF) and brain biopsy, as well as  
87 immunohistochemical and serological assays [4]. Failure to detect a causative agent by such  
88 routine laboratory diagnostics may reflect a lack of diagnostic tests for rare, novel or  
89 divergent pathogens, limited volume of CNS samples, and overlapping clinical presentation  
90 caused by infectious and non-infectious processes [5].

91 The incidence of all-cause childhood encephalitis (including infection-associated  
92 encephalopathy) is estimated to be between 3.8 and 5.0 per 100,000 population aged  $\leq 14$   
93 years [6]. The leading causes are picornaviruses (enteroviruses and parechoviruses), herpes  
94 simplex viruses 1 and 2, influenza (infection associated encephalopathy), bacterial meningo-  
95 encephalitis and immune-mediated causes such as acute disseminated encephalo-myelitis  
96 (ADEM) and anti-N-methyl-D-aspartate receptor (NMDAr) encephalitis [7]. The burden of  
97 disease is considerable, with 49% admitted to ICU, a case-fatality rate of 5%, and 27% of  
98 cases showing neurodisability at discharge from hospital [7].

99 Metagenomic next-generation sequencing (mNGS) has successfully identified a broad  
100 range of infectious agents in a range of clinical syndromes [8-10] and is gradually being  
101 established as a powerful and reliable diagnostic platform [8]. Indeed, mNGS has identified  
102 an increasing number of novel or unexpected pathogens associated with encephalitis [11].  
103 Total RNA sequencing – meta-transcriptomics – may be especially powerful as it provides a  
104 simple way to characterise all the actively transcribing microbes in a sample and estimate  
105 their abundance [12-14]. Not only does total RNA sequencing identify the RNA viruses  
106 present in a sample, but also those DNA viruses, bacteria, parasites and fungi that are actively  
107 transcribing RNA [15].

108 The Australian Childhood Encephalitis (ACE) study has comprehensively identified,  
109 collected data, and reviewed cases of this severe syndrome nationally through active sentinel  
110 hospital surveillance since 2013, and requested banking of salvaged laboratory biospecimens  
111 from cases [7]. Herein, we describe the use of total RNA sequencing on samples of differing  
112 tissue types obtained from 18 cases of childhood encephalitis categorised as having unknown  
113 cause. Notably, several common respiratory viruses, including human seasonal coronaviruses  
114 and rhinoviruses, were identified in samples outside of the CNS and potentially caused the  
115 disease process in these cases.

116

## 117 **Results**

### 118 **Clinical evaluation**

119 A total of 18 cases, representing patients from four Australian states (Figure 1A), were  
120 chosen for study. These cases had previously been reviewed and confirmed to have  
121 encephalitis using the Brighton criteria and International Encephalitis Consortium (IEC)  
122 definitions [7], but with unknown causality (Table 1). The sex ratio of patients was 1.57:1  
123 male to female, with ages ranging from neonates to twelve years (average, 4.5 years) such  
124 that only pre-adolescent children were considered (Table 1).

125 Of the 18 unknown encephalitis patients, abnormal neuroimaging (MRI/CT) was found  
126 in 14/18, and EEG findings consistent with encephalitis were observed in 10/18 (Table 1).  
127 Most patients had fever (13/18) and lethargy/drowsiness (11/18). Irritability was recorded in  
128 6/18 patients, ataxia/unusual behaviour in 7/18, decreased level of consciousness (LOC) in  
129 5/18, confusion in 4/18, headache in 6/18, vomiting in 5/18, poor feeding in 4/18 and status  
130 epilepticus in 2/18 (Table 1). In addition, diarrhoea, cough, rash, convergent squint, coryza,  
131 eye deviation, dysarthria, facial droop, urinary retention and hyperreflexia were observed in  
132 one or two cases (Table 1). One patient was reported with respiratory illness in the two weeks  
133 prior to admission. Three patients were transferred to an intensive care unit (ICU) within 24  
134 hours of admission. One patient with severe combined immunodeficiency (SCID) died. Two  
135 patients showed clinical improvement with corticosteroid treatment.

**Table 1.** Demographic and clinical characteristics of the 18 patients studied here.

Case No.	Sex/Age	Respiratory symptoms		Gastro-intestinal symptoms		CNS Inflammation					Reduced Responsiveness				*Focal neurological signs	Brighton criteria	International encephalitis consortium criteria
						Fever	CSF pleocytosis	CSF WCC	MRI changes	EEG changes	Absent environment	Absent eye	Decreased arousability	Seizure LOC			
1	F/3.2mo	Y		Y	Y	11	Y	Y	Y	Y	Y	Y	Y	Y	Level 2	Probable	
2	M/7.1yo	Y		Y	Y	501			N/A	Y				Y	Level 2	Possible	
3 <sup>#</sup>	M/1.1yo	Y		Y		3	Y			Y	Y	Y	Y	Y	Level 2	Probable	
4	M/7.4yo	Y		Y		2	N/A	Y		Y		Y			Level 2	Possible	
5	M/9.5yo			Y		0		Y		Y	Y	Y		Y	Level 2	Possible	
6	M/2.6yo			Y		1			N/A	Y	Y	Y		Y	Level 3	Possible	
7	F/1.1yo	Y			Y	21	Y	Y		Y	Y	Y	Y	Y	Level 2	Probable	
8 <sup>†</sup>	M/8.5yo			Y	Y	29	Y	N/A		Y	Y	Y		Y	Level 2	Probable	
9	F/3.8wks			Y	Y	65	Y	Y		Y		Y		Y	Level 2	Possible	
10 <sup>†</sup>	M/9.9yo		Y		Y	29	Y	N/A				Y			Level 2	Probable	
11	M/3mo				Y	72	Y	N/A	N/A	Y				Y	Level 3	Probable	
12 <sup>†</sup>	M/3.6yo		Y			0	Y	N/A						Y	Level 3	Probable	
13	F/3.4yo	Y	Y	Y	Y	21	Y			Y	Y	Y	Y	Y	Level 2	Probable	
14	M/12.6yo	Y	Y		Y	66		N/A		Y	Y	Y	Y	Y	Level 2	Possible	
15	M/8.1yo			Y		6	Y	Y		Y	Y	Y		Y	Level 2	Probable	
16	F/8.6mo				Y	31	Y	Y		Y	Y	Y	Y	Y	Level 2	Probable	
17 <sup>##</sup>	F/3.3yo			Y	N/A	N/A	N/A					Y	Y	Y	Level 3	Probable	
18	F/7.8yo			Y	Y	7	Y	Y		Y	Y	Y	Y	Y	Level 2	Probable	



Y = Yes, N/A = Not Done. All cases had an initial expert panel diagnosis of Unknown Encephalitis. \* Y is indicative of cases with one or more of the following: focal seizure, cranial nerve abnormality, visual impairment, motor weakness, altered deep tendon reflexes, cerebellar dysfunction, abnormal movement, or any other focal neurological signs. Respiratory symptoms included cough/coryza and increased work of breath requiring mechanical ventilation for both cases, gastrointestinal symptoms include diarrhoea and/or vomiting.

#This patient was with severe combined immunodeficiency (SCID) and the outcome was death.

##This patient was reported with respiratory illness in the previous 2 weeks before admission.

†These patients were transferred to intensive care unit (ICU) within 24 hours of admission.

1 Diagnostic testing for a range of viral agents by PCR on CSF, blood/plasma, sputum and  
2 stool samples were performed in the local hospitals. All were negative with the exception of  
3 one positive detection of rotavirus from a stool sample, and one detection each of rhinovirus  
4 and coronavirus (OC43) in respiratory samples (Table S1). None were considered significant  
5 to the clinical presentation. Similarly, serological tests were negative (not consistent with  
6 acute infection) for all cases (Table S1). Some cases were also tested for antibodies against  
7 ganglioside, muscle specific tyrosine kinase (MUSK), acetylcholine receptor (AChR), N-  
8 Methyl-D-Aspartate receptor (NMDAR), voltage-gated potassium channel (VGKC) and  
9 neuromyelitis optica (NMO). All were negative (Table S1).

10 A multidisciplinary expert team (PNB, RD, AK, CAJ) re-reviewed clinical presentation,  
11 available diagnostic testing using published criteria for assigning causation in encephalitis  
12 and criteria for clinically diagnosing autoimmune encephalitis [16, 17]. Following this  
13 review, nine were considered to likely have infectious causes, six immune-mediated causes,  
14 and three could not be further classified (Table 2).

15 **Table 2.** Possible pathogen identification by metagenomic next-generation sequencing (mNGS) and final diagnosis.

Case No.	Initial Diagnosis	Independent Clinical Review	Virus	Specimen	Abundance (RPM)	mNGS conclusion	Final Diagnosis
1	Unknown encephalitis	Possible infectious	Human Rhinovirus A9	NPA	8399	Possible	Possible infectious encephalitis - Human Rhinovirus A9
2	Unknown encephalitis	Unclear cause					Encephalitis – unknown cause
3	Unknown encephalitis	Possible infectious	Human coronavirus OC43 WU Polyomavirus	NPA NPA	523673 1548	Possible/ indeterminate	Possible infectious encephalitis - Human coronavirus OC43
4	Unknown encephalitis	Possible infectious					Encephalitis – unknown cause
5	Unknown encephalitis	Possible immune mediated					Possible immune mediated encephalitis
6	Unknown encephalitis	Unclear cause					Encephalitis – unknown cause
7	Unknown encephalitis	Possible infectious					Encephalitis – unknown cause
8	Unknown encephalitis	Possible immune mediated					Possible immune mediated encephalitis
9	Unknown encephalitis	Possible infectious	Human coronavirus OC43	Blood	82	Possible	Possible infectious encephalitis - Human coronavirus OC43
10	Unknown encephalitis	Possible immune mediated	JC polyomavirus	Urine	80	Unlikely	Possible immune mediated encephalitis
11	Unknown encephalitis	Possible infectious	Human Rhinovirus B52 Human Rhinovirus B52	NPA Stool	454711 87	Possible/ indeterminate	Possible infectious encephalitis - Human Rhinovirus B52

12	Unknown encephalitis	Possible immune mediated					Possible immune mediated encephalitis
13	Unknown encephalitis	Unclear cause					Encephalitis – unknown cause
14	Unknown encephalitis	Possible infectious					Encephalitis – unknown cause
15	Unknown encephalitis	Possible immune mediated	Human coronavirus OC43	NPA	170	Unlikely	Possible immune mediated encephalitis
16	Unknown encephalitis	Possible infectious					Encephalitis – unknown cause
17	Unknown encephalitis	Possible infectious	Human coronavirus HKU1 Human coronavirus HKU1 Human picobirnavirus	Rectal Swab Respiratory Stool	6060 2939 2124	Possible Possible Unlikely	Possible infectious encephalitis - Human coronavirus HKU1
18	Unknown encephalitis	Possible immune mediated					Possible immune mediated encephalitis

## 17 **Meta-transcriptomic exploration of potential infectious microbes**

18 A total of 43 specimens, comprising CSF, blood, serum, urine, stool, rectal swabs (rectal  
19 SW), nasal swabs (respiratory SW), throat swabs (throat SW), nasopharyngeal aspirates  
20 (NPA) and endotracheal aspirates (ETA), were utilised in metagenomic testing (Figure 1B).  
21 All 43 samples were individually examined using meta-transcriptomics, generating 2.77  
22 billion raw paired-end reads in total (between 12.2 and 81.0 million reads per sample) (Table  
23 S2). For each library, 48.46 to 85.79% of the reads were retained after removal of low  
24 complexity and redundant reads (Figure S1, Table S2), and 1.10 to 80.19% of these reads  
25 were subsequently retained after removal of human reads (Figure S1, Table S2). The resultant  
26 sequence reads and assembled contigs were annotated against NCBI reference databases,  
27 revealing a number of microbes, including potential pathogens. These are described in more  
28 detail below.

## 30 **Detection of viral sequences in clinical samples of encephalitis**

31 Blastx comparisons against the nr database identified at least 7 virus species (5 RNA viruses  
32 and 2 DNA viruses) associated with human infection (Figure 2). The total virus positive rate  
33 of specimens was 23% (10/43), while the total virus positive rate of patients was 39% (7/18).  
34 All the viruses identified are known to be associated with overt disease, with the exception of  
35 a picobirnavirus present in one stool sample that may represent a bacteriophage [18]. Among  
36 these viruses, human coronavirus OC43 (HCoV-OC43) was present in three cases, while  
37 human coronavirus HKU1 (HCoV-HKU1), human rhinovirus A (HRVA), human rhinovirus

38 B (HRVB), JC polyomavirus (JCPyV) and WU polyomavirus (WUPyV) were detected in  
39 one case each. Finally, HCoV-HKU1 was detected in both respiratory swab and rectal swab  
40 of case 17, while HRVB was detected in both NPA and stool of case 11 (Figure 2).  
41 CSF was available for testing from 9/18 cases and we observed a relative absence of possible  
42 virus sequence detections amongst these CSF samples.

43 Virus expression levels were quantified by estimating their relative abundance (RPM,  
44 reads per million). Accordingly, the highest virus abundance was 523,673 RPM (HCoV-  
45 OC43, case 03 in NPA), followed by 454,710 RPM (HRV-B52, case 11 in NPA) (Figure 2,  
46 Table 2). Viruses with greater than 1,000 RPM ( $> 0.1\%$  of total reads) included HCoV-  
47 HKU1 (case 17, in rectal swab and respiratory swab), HRV-A9 (case 01, in NPA), HPBV  
48 (case 17, in stool) and WU polyomavirus (case 03, in NPA) (Figure 2, Table 2). The  
49 abundance level of HCoV OC43-was greater than 100 RPM in case 15 (throat swab) and  
50 lower than 100 RPM in case 09 (blood) (Figure 2, Table 2).

51 To identify specific viral genotypes/lineages and their epidemiological origins,  
52 phylogenetic analyses were performed using the resulting complete or partial virus genomes  
53 (Table S3). This revealed that all HCoV-HKU1, HCoV-OC43, WUPyV and JCPyV  
54 sequences determined here were  $>99.5\%$  identical to the most closely related sequences  
55 available on publicly available data bases (Table S3), belonging to genotypes B, G, 3b and  
56 2B, respectively (Figure 3A, 3B, 3E and 3F). Two sequences of human rhinovirus B52 -  
57 HRV-B52/11-4818/VIC/AU/2019 and HRV-B52/11-4817/VIC/AU/2019 - detected in an  
58 NPA and stool specimen from case 11 shared 100% sequence identity with each other yet

59 were relatively distant to known viruses (92.8% nt identity) (Figure 3C, Table S3), such that  
60 it likely represents a new genotype of this virus. The human rhinovirus A9 identified here,  
61 HRV-A9/01-14618/NSW/AU/2019, exhibited 96.5% sequence identity to the most closely  
62 publicly available sequence (Figure 3D, Table S3).

63 One picobirnavirus was identified from one stool sample (case 17), and the near  
64 complete sequences of two segments were obtained (Figure 4B). Segment 1 contains two  
65 open reading frames, with ORF2 encoding the viral capsid protein and ORF1 encoding a  
66 hypothetical protein with unknown function, while segment 2 contains an ORF encoding the  
67 viral RNA-dependent RNA polymerase (RdRp) gene (Figure 4B). The conserved motif of the  
68 ribosomal binding site (RBS) nucleotide sequence (AGGAGG) is present upstream of the  
69 ORF2 of segment 1 and RdRp of segment 2 (Figure 4B). Two copies of the conserved  
70 ExxRxxNxxxE aa motif are identifiable un ORF2 of segment 1(Figure 4B). Phylogenetic  
71 analysis based on RdRp showed that HPBV/17-26618/WA/AU/2019 is related to primate  
72 PBVs within genogroup 1 (Figure 4A), and the RdRp shared 72.4% amino acid sequence  
73 identity with the corresponding protein of macaque PBV (AVD54068) (Table S3).

74

## 75 **Characterization of infecting bacteria**

76 We characterised microbial taxonomic clades belonging to seven phyla and 74 species  
77 (Figure 5A). The dominant bacterial families identified were *Enterobacteriaceae* (63.64%,  
78 estimated using MetaPhlan2), followed by *Veillonellaceae* (10.18%), *Enterococcaceae*  
79 (6.07%), *Pseudomonadaceae* (5.89%), *Clostridiales family xi incertae* (5.30%),

80 *Streptococcaceae* (2.75%), and *Bacteroidaceae* (1.45%) (Figure 5). As *Escherichia coli*,  
81 unclassified *Escherichia* and unclassified *Veillonella* were observed in almost every library  
82 (Figure 6), they were considered unlikely to be infectious agents. *Enterococcus faecalis*, as  
83 part of intestinal microbiota and an opportunistic pathogen, was detected in two sterile sites:  
84 blood (case 06) and CSF (case 14), although with extremely low abundance (1 and 14 RPM;  
85 53 and 549 reads, respectively) (Figure 6). In other cases, the bacteria identified were known  
86 human colonisers or of indeterminate pathogenic status and were observed in non-sterile sites  
87 making them unlikely pathogens (Figure 6). No bacterial sequences detected were considered  
88 potentially pathogenic.

89

## 90 **Correlation between results from clinical evaluation and mNGS**

91 Among those cases with likely infectious causes following clinical evaluation, seven  
92 harboured viruses at non-sterile sites (NPA, urine, stool, throat swab, rectal swab and  
93 respiratory swab) and one in a sterile site (blood) (Table 2). Case 03, a 1-year-old boy with  
94 severe combined immunodeficiency (SCID), had the highest abundance of human  
95 coronavirus OC43 (523,673 RPM) and medium abundance of Wu polyomavirus (1548RPM)  
96 in NPA, indicating a possible synergistic interaction between these two viruses. Although  
97 human coronavirus OC43 has not usually been considered a pathogen capable of causing  
98 encephalitis, it's very high abundance and clinically likely infectious cause makes it a  
99 possible pathogen in this case. Human rhinoviruses (HRV-A9 and HRV-B52), that are  
100 commonly associated with respiratory diseases, were detected in NPA of case 01 and 11, with



101 high to extremely high abundance (8399-454,711 RPM) (Figure 2, Table 2), respectively.  
102 These cases were clinically considered likely infectious, suggesting that the two rhinoviruses  
103 identified may be the causative pathogens. JC polyomavirus and human coronavirus OC43  
104 were detected in cases 10 and 15 at relatively low abundance (80 and 170 RPM,  
105 respectively). Although both these viruses have previously been associated with encephalitis  
106 [19, 20], their low abundance and potential constitutive expression (JCV) make them less  
107 likely to be pathogens in these two cases. Importantly, although HCoV-OC43 was not highly  
108 abundant in case 09, it was detected in blood (sterile site), which indicates likely  
109 pathogenicity in this case (Figure 2, Table 2). In addition, a high abundance of human  
110 coronavirus HKU1 were detected in both respiratory swab and rectal swab of case 17, who  
111 was reported with a respiratory illness in the before admission, suggesting potential  
112 pathogenicity in this case.

113 Among those cases with likely immune-mediated cause following clinical evaluation,  
114 viruses were detected in only two: case 10 (JCV) and case 15 (HCoV-OC43). However, in  
115 both cases the viruses were at very low abundance and present at non-sterile sites and so were  
116 considered unlikely pathogens. The relative lack of pathogen sequences among those cases  
117 with likely immune-mediated causes was notable.

118

## 119 **Discussion**

120 Identification of a causative agent in infectious encephalitis is most validly achieved by  
121 obtaining a specimen directly at the site of inflammation, such as CSF or brain biopsy tissue,

122 although the latter is seen as a last resort as sampling comes with associated risks [4].  
123 Therefore, in most cases, CSF is considered the best surrogate specimen for the assessment of  
124 neurological disorders [21]. Unlike routine laboratory methods that are limited to the  
125 detection of known or related agents, mNGS offers unprecedented opportunities to detect a  
126 broad range of microbes including their relative abundance and has recently been employed  
127 successfully in detecting a diverse array of potential pathogens not previously associated with  
128 CNS disease [22], including astroviruses [3, 23, 24] and arenavirus [25] in cases of  
129 encephalitis in immunocompromised and transplant-associated patients. Also of note was that  
130 a pegivirus, although considered non-pathogenic, was detected using mNGS in a patient with  
131 encephalitis [26], and this technique has recently detected parasitic worms, bacteria, and  
132 fungi in CSF specimens from patients with CNS infection of unknown aetiology [5, 11, 27-  
133 29].

134 Importantly, in instances where a CSF sample is unavailable or mNGS testing of CSF  
135 fails to detect a pathogen, other sites and samples including respiratory tract (nasal and throat  
136 swabs, NPA), gastrointestinal tract (faeces, rectal swab), urine or blood may provide an  
137 additional indirect opportunity to test for the presence of potential pathogens that might have  
138 transferred in the brain [4]. Further, for some well-established CNS pathogens, CSF testing  
139 for viral nucleic acid shows low sensitivity. For example, flaviviruses and enterovirus A71  
140 have been detected in throat swabs, stool or urine from patients with clinical encephalitis, yet  
141 were absent in CSF or plasma/serum collected concurrently [30-32]. Among the cases with  
142 CSF available for testing (9/18 cases) here, none showed the presence of a possible viral

143 pathogen. In contrast, four respiratory viruses – human rhinovirus A9, human rhinovirus B52,  
144 human coronavirus OC43 and human coronavirus HKU1 – were detected in respiratory and  
145 gastrointestinal samples (NPA, respiratory swab and rectal swab) from four cases, all of  
146 which were in high abundance (>1,000 RPM), indicating that they are experiencing active  
147 replication in these patients. Further, these viruses were detected in patients considered likely  
148 to have an infectious aetiology in an independent clinical evaluation and so are considered  
149 potential pathogens.

150 Human coronaviruses are respiratory viruses infrequently reported with neuroinvasive  
151 properties in both mice and humans [20, 33, 34]. One study suggested that coronavirus  
152 infection in the central nervous system is as common as in respiratory tract, although with  
153 distinct features [35]. HCoV-OC43 has been identified in CSF and brain tissue in isolated  
154 cases of children with acute encephalomyelitis or ADEM [20, 36]. In mice, HCoV-OC43 has  
155 been shown to directly invade the CNS via the olfactory route, indicating that intranasal  
156 infection may play a role in propagating viruses [20, 37]. Our detection of HCoV in NPA and  
157 respiratory samples in high abundance suggests they are possible causative agents, and that  
158 the olfactory pathway needs further consideration as a route, albeit infrequent, for  
159 neuroinvasion in humans [33, 38]. The potential role of human coronaviruses in acute  
160 neurological disease has been further highlighted by the growing evidence of neurological  
161 disease of multiple phenotypes as infrequent clinical presentation of SARS-CoV-2 infection  
162 [39-42].

163 Rhinoviruses (genus *Enterovirus*) are the cause of various respiratory illnesses [38].  
164 Unlike some members within the same genus (polioviruses, echovirus, coxsackieviruses,  
165 enteroviruses) often implicated in encephalitis, rhinoviruses are discounted as potential  
166 causes of encephalitis in consensus criteria [43]. However, although rhinoviral CNS infection  
167 is rare, there are reports of human rhinovirus A and B in respiratory specimens associated  
168 with acute neurological disease including acute cerebellitis and meningitis, respectively, and  
169 one rhinovirus (unknown species) was detected in CSF in a case of sepsis-like illness [44-46].  
170 Further, enterovirus D68 is acknowledged as an emerging neurotropic enterovirus with  
171 predominant replication in the respiratory tract [47, 48], suggesting that members of the  
172 *Enterovirus* genus may have neuropathic potential more broadly. Although the two species of  
173 rhinovirus detected in this study were identified in in nasopharyngeal aspirates, on the basis  
174 of clinical evaluation and mNGS analysis they are considered possible causative agents.  
175 Targeted assays of the CSF or antibody tests could be beneficial for pathogen determination  
176 in future cases.

177 Another possible explanation for the pathogenicity of these respiratory viruses at non-  
178 CSF sites is that they represent para-infectious encephalitis resulting from indirect CNS  
179 pathogenicity. A variety of severe encephalopathy/encephalitis syndromes have been  
180 described in association with viruses such as influenza, adenovirus and human herpes virus-6,  
181 and it is possible that other respiratory viruses could produce disease via these mechanisms  
182 [38, 49-53]. It is clear that larger studies are needed to better understand the role of non-CNS  
183 samples in the detection of candidate pathogens amongst cases of encephalitis with otherwise

184 unknown cause. These studies should involve the testing of non-CNS samples in combination  
185 with molecular and serological CSF and serum investigations.

186 The frequency and range of bacterial reads identified in almost all specimens analysed  
187 highlights the challenge of applying and interpreting mNGS particularly to non-sterile  
188 samples. Most reads corresponded to known human colonisers and/or organisms with  
189 questionable pathogenicity. An exception was *E. coli* that was detected in sterile site samples  
190 from several cases, but discounted given that reads were present in all samples analysed.  
191 Similarly, *E. faecalis* was present in two sterile site samples in two cases, but at very low  
192 abundance in sterile site specimens in two cases, and we were unable to confirm these  
193 infections by PCR. Notably, all the cases studied received empiric antibiotic treatment with a  
194 third-generation cephalosporin to which enterococci are inherently resistant. Concurrent or  
195 preceding antibiotic usage is an important consideration in mNGS studies where treatment  
196 may bias detection to resistant bacterial species [9].

197 An additional insight from this study is the apparent utility of clinical definitions of  
198 immune-mediated encephalitis. Among the unknown encephalitis cases under enhanced  
199 evaluation here, six were considered likely to be immune-mediated. Despite a similar number  
200 and spectrum of samples available for mNGS, we found no possible pathogens using mNGS  
201 among these six cases compared with possible pathogens in five of nine cases clinically  
202 considered likely to be infectious by an independent clinical review panel. The frequency of  
203 likely immune-mediated encephalitis in this case series of encephalitis of unknown cause  
204 emphasises the need for further research to identify diagnostic biomarkers.

205 It is not possible to definitively determine that the viruses identified using mNGS here  
206 were the causes of the encephalitis in each individual case studied. However, the combination  
207 of enhanced clinical evaluation with mNGS appears a fruitful way forward in evaluation of  
208 cases of unknown encephalitis [9].

209

## 210 **Methods**

### 211 **Ethics statement**

212 This study was performed under the ethical approval of the Sydney Children's Hospitals  
213 Network Human Research Ethics Committee (HREC/13/SCHN/191).

214

### 215 **Enrolment criteria and case definition**

216 The cases selected in this study all met the case definition of encephalitis [54]. This included  
217 patients aged  $\leq 14$  years admitted to hospital with encephalopathy, altered consciousness  
218 that persisted for longer than 24 hours, including lethargy, irritability, or a change in  
219 personality and behaviour, and at least two of the following criteria: (i) fever or history of  
220 fever ( $\geq 38^{\circ}\text{C}$ ) during the presenting illness, (ii) seizures and/or focal neurological, (iii)  
221 abnormal findings on electroencephalographic (EEG) consistent with encephalitis, and (iv)  
222 abnormal results of neuroimaging (CT or MRI) suggestive of encephalitis (Table 1). In  
223 addition, each of the study subjects tested negative with routine diagnostic protocols.

224 All samples were collected from diagnostic laboratories between March 2014 and  
225 December 2016. All specimens were originally collected by trained clinicians using sterile

226 swabs or aseptic technique and were immediately sent to local laboratories where diagnostic  
227 testing was undertaken. Following diagnostic testing, residual samples were stored at -20°C.  
228 Following collection for research purposes, informed consent was obtained from  
229 parents/guardians for research testing and specimens were then placed into -80°C storage  
230 locally and transferred in batches on dry ice to a central specimen repository where they were  
231 stored in a -80°C freezer.

232

### 233 **RNA extraction, library construction and sequencing**

234 Samples were subjected to RNA extraction using the RNeasy plus universal kit (QIAGEN,  
235 Chadstone Centre, Victoria, Australia). The concentration and quality of final extractions  
236 were examined using a NanoDrop spectrophotometer (ThermoFisher Scientific, USA). The  
237 Trio RNA-Seq kit (NuGEN Technologies, USA) was used for library preparation in all cases  
238 as it targets low concentration RNA samples (as low as 500 pg) [55]. Paired-end (150 bp)  
239 sequencing of these RNA library was performed using the Illumina NovaSeq platform. All  
240 library preparation and sequencing steps were performed by Australian Genome Research  
241 Facility (AGRF), Melbourne.

242

### 243 **Microbial characterization**

244 For each library/case, quality control was performed and adaptor sequences and low-  
245 quality/low-complex reads were removed using BBmap ([https://jgi.doe.gov/data-and-](https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/)  
246 [tools/bbtools/bb-tools-user-guide/bbmap-guide/](https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/)) and CD-HIT-DUP [56]. Human reads were

247 removed by mapping to the human genome. Non-human reads were then compared against  
248 reference virus database downloaded from GenBank and the NCBI non-redundant protein  
249 database using Blastn and Diamond [57] blastx, respectively, with e-value thresholds of  $1 \times$   
250  $10^{-10}$  and  $1 \times 10^{-4}$ . Blast hits were then annotated by taxonomy. Reads were *de novo* assembled  
251 using Megahit [58, 59] from the virus-positive library in which they were identified based on  
252 the blast procedure described above. In cases with low genome coverage, reads were directly  
253 mapped to the sequence of a close relative, and a consensus genome was obtained from the  
254 mapped reads. To exclude contamination due to index hopping, for each virus only those  
255 present at  $>0.1\%$  of the highest viral abundance were considered true positives. Sequence  
256 specific primers were designed, and RT-PCR and Sanger sequencing were performed to  
257 verify and confirm the presence of viruses with highly similar sequences that appeared in  
258 multiple libraries.

259 Virus abundance were estimated as Reads Per Million (RPM) [55], calculated by using  
260 the relation "mapped reads / total reads \* one million". For picobirnavirus, open reading  
261 frames were predicted using orffinder (<https://www.ncbi.nlm.nih.gov/orffinder/>) and gene  
262 annotated against the conserved domain database (CDD) [60].

263 The resulting complete or partial virus genomes (Table S3), as well as related  
264 background viruses from GenBank, were aligned using MAFFT version 7 [61] and subjected  
265 to phylogenetic analysis using the maximum likelihood method available in PhyML 3.0 [62]  
266 employing the General Time Reversible (GTR) model of nucleotide substitution with a  
267 gamma distribution of among-site rate variation and 1000 bootstrap replicates.



268 Bacterial taxonomic profiling was initially performed using MetaPhlAn2 [63] with  
269 default parameters, mapping the non-human sequence reads to a set of ~1 million unique  
270 clade-specific marker genes from ~13,500 bacterial and archaeal species.

271

## 272 **Data availability**

273 All non-human sequence reads generated here have been deposited on the NCBI Sequence  
274 Read Archive (SRA; BioProject accession PRJNA633210).

275

## 276 **Clinical evaluation**

277 All 18 cases had previously undergone clinical review as part of the Australian Childhood  
278 Encephalitis study and been determined to have an unknown cause [7]. A clinical evaluation  
279 panel was convened comprising a clinical paediatric neurologist (RD), paediatric infectious  
280 disease physician (CJ), clinical epidemiologist (PB) and clinical microbiologist (AK) who re-  
281 evaluated each case in terms of clinical presentation, available diagnostic testing and  
282 response to empiric therapies using published criteria for assigning causation in encephalitis  
283 [43] and clinically diagnosing autoimmune encephalitis [16]. This panel was blinded to the  
284 mNGS results.

285

## 286 **Logic model for determining pathogenic potential of mNGS detections**

287 We applied a logic model (Figure S2) to determine the likely significance of mNGS results  
288 based upon the nature of the sample from which mNGS detection occurred, the organism

289 abundance and pathogenicity, and accounting for the enhanced clinical evaluation findings to  
290 arrive at a final clinical diagnosis.

291 **Acknowledgments**

292 We acknowledge The University of Sydney HPC service (Artemis) for providing high-  
293 performance computing resources that have contributed to the research reported in this paper.

294

295 **Author Contributions**

296 **Conceptualization:** Cheryl A. Jones, Philip N. Britton, Edward C. Holmes.

297 **Data curation:** Ci-Xiu Li, Rebecca Burrell.

298 **Formal analysis:** Ci-Xiu Li, Rebecca Burrell, Philip N. Britton, Edward C. Holmes.

299 **Funding acquisition:** Cheryl A. Jones, Philip N. Britton, Edward C. Holmes.

300 **Investigation:** Russell C. Dale, Alison Kesson, Christopher C Blyth, Julia E Clark, Nigel

301 Crawford, Cheryl A. Jones

302 **Methodology:** Ci-Xiu Li, Rebecca Burrell

303 **Resources:** Rebecca Burrell, Alison Kesson, Christopher Blyth, Julia Clark, Nigel Crawford.

304 **Writing - original draft:** Ci-Xiu Li.

305 **Writing - review & editing:** Ci-Xiu Li, Rebecca Burrell, Russell C. Dale, Christopher C

306 Blyth Julia E Clark, Cheryl A. Jones, Philip N. Britton, Edward C. Holmes.

## 307 **References**

- 308 1. Granerod J, Tam CC, Crowcroft NS, Davies NWS, Borchert M, Thomas SL. Challenge  
309 of the unknown: A systematic review of acute encephalitis in non-outbreak situations.  
310 Neurology. 2010; 75: 924-932. doi: 10.1212/WNL.0b013e3181f11d65. PMID:  
311 20820004.
- 312 2. Singh TD, Fugate JE, Rabinstein AA. The spectrum of acute encephalitis Causes,  
313 management, and predictors of outcome. Neurology. 2015; 84: 359-366. doi:  
314 10.1212/Wnl.0000000000001190. PMID: 25540320.
- 315 3. Brown JR, Morfopoulou S, Hubb J, Emmett WA, Ip W, Shah D, et al. Astrovirus  
316 VA1/HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised  
317 patients. Clin Infect Dis. 2015; 60: 881-888. doi: 10.1093/cid/ciu940. PMID: 25572899.
- 318 4. Kennedy PGE, Quan PL, Lipkin WI. Viral encephalitis of unknown cause: current  
319 perspective and recent advances. Viruses. 2017; 9: 138. doi: 10.3390/v9060138. PMID:  
320 28587310.
- 321 5. Wilson MR, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu GX, et al. Actionable  
322 diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med. 2014;  
323 370: 2408-2417. doi: 10.1056/NEJMoa1401268. PMID: 24896819.
- 324 6. Britton PN, Khoury L, Booy R, Wood N, Jones CA. Encephalitis in Australian children:  
325 contemporary trends in hospitalisation. Arch Dis Child. 2016; 101: 51-56. doi:  
326 10.1136/archdischild-2015-308468. PMID: 26475868.

- 327 7. Britton PN, Dale RC, Blyth CC, Clark JE, Crawford N, Marshall H, et al. Causes and  
328 clinical features of childhood encephalitis: a multicenter, prospective cohort study. *Clin*  
329 *Infect Dis.* 2020; 70: 2517-2526. doi: 10.1093/cid/ciz685. PMID: 31549170.
- 330 8. Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for  
331 pathogen detection. *Annu Rev Pathol.* 2019; 14: 319-338. doi: 10.1146/annurev-  
332 pathmechdis-012418-012751. PMID: 30355154.
- 333 9. Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, Neuhaus J, et al. Clinical  
334 metagenomic sequencing for diagnosis of meningitis and encephalitis. *N Engl J Med.*  
335 2019; 380: 2327-2340. doi: 10.1056/NEJMoa1803396. PMID: 31189036.
- 336 10. Chiu CY, Miller SA. Clinical metagenomics. *Nat Rev Genet.* 2019; 20: 341-355. doi:  
337 10.1038/s41576-019-0113-7. PMID: 30918369.
- 338 11. Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, et al.  
339 Chronic meningitis investigated via metagenomic next-generation sequencing. *JAMA*  
340 *Neurol.* 2018; 75: 947-955. doi: 10.1001/jamaneurol.2018.0463. PMID: 29710329.
- 341 12. Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, et al. Best  
342 practices for analysing microbiomes. *Nat Rev Microbiol.* 2018; 16: 410-422. doi:  
343 10.1038/s41579-018-0029-9. PMID: 29795328.
- 344 13. Shi M, White VL, Schlub T, Eden JS, Hoffmann AA, Holmes EC. No detectable effect  
345 of *Wolbachia* wMel on the prevalence and abundance of the RNA virome of *Drosophila*

- 346 *melanogaster*. Proc Biol Sci. 2018; 285: 20181165. doi: 10.1098/rspb.2018.1165. PMID:  
347 30051873.
- 348 14. Shi M, Lin XD, Tian JH, Chen LJ, Chen X, Li CX, et al. Redefining the invertebrate  
349 RNA virosphere. Nature. 2016; 540: 539-543. doi: 10.1038/nature20167. PMID:  
350 27880757.
- 351 15. Shi M, Zhang YZ, Holmes EC. Meta-transcriptomics and the evolutionary biology of  
352 RNA viruses. Virus Res. 2018; 243: 83-90. doi: 10.1016/j.virusres.2017.10.016. PMID:  
353 29111455.
- 354 16. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach  
355 to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15: 391-404. doi:  
356 10.1016/S1474-4422(15)00401-9. PMID: 26906964.
- 357 17. Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, et al.  
358 Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient.  
359 Neurol Neuroimmunol Neuroinflamm. 2020; 7: e663. doi:  
360 10.1212/NXI.0000000000000663. PMID: 31953309.
- 361 18. Krishnamurthy SR, Wang D. Extensive conservation of prokaryotic ribosomal binding  
362 sites in known and novel picobirnaviruses. Virology. 2018; 516: 108-114. doi:  
363 10.1016/j.virol.2018.01.006. PMID: 29346073.

- 364 19. Tan CS, Koranik IJ. Progressive multifocal leukoencephalopathy and other disorders  
365 caused by JC virus: clinical features and pathogenesis. *Lancet Neurol.* 2010; 9: 425-437.  
366 doi: 10.1016/S1474-4422(10)70040-5. PMID: 20298966.
- 367 20. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, et al.  
368 Human coronavirus OC43 associated with fatal encephalitis. *N Engl J Med.* 2016; 375:  
369 497-498. doi: 10.1056/NEJMc1509458. PMID: 27518687.
- 370 21. Ellul M, Solomon T. Acute encephalitis - diagnosis and management. *Clin Med.* 2018;  
371 18: 155-159. doi: 10.7861/clinmedicine.18-2-155. PMID: 29626021.
- 372 22. Brown JR, Bharucha T, Breuer J. Encephalitis diagnosis using metagenomics:  
373 application of next generation sequencing for undiagnosed cases. *J Infect.* 2018; 76: 225-  
374 240. doi: 10.1016/j.jinf.2017.12.014. PMID: 29305150.
- 375 23. Sato M, Kuroda M, Kasai M, Matsui H, Fukuyama T, Katano H, et al. Acute  
376 encephalopathy in an immunocompromised boy with astrovirus-MLB1 infection  
377 detected by next generation sequencing. *J Clin Virol.* 2016; 78: 66-70. doi:  
378 10.1016/j.jcv.2016.03.010. PMID: 26991054.
- 379 24. Quan PL, Wagner TA, Briese T, Torgerson TR, Hornig M, Tashmukhamedova A, et al.  
380 Astrovirus encephalitis in boy with X-linked agammaglobulinemia. *Emerg Infect Dis.*  
381 2010; 16: 918-925. doi: 10.3201/eid1606.091536. PMID: 20507741.

- 382 25. Palacios G, Druce J, Du L, Tran T, Birch C, Briese T, et al. A new arenavirus in a cluster  
383 of fatal transplant-associated diseases. *N Engl J Med*. 2008; 358: 991-998. doi:  
384 10.1056/NEJMoa073785. PMID: 18256387.
- 385 26. Tuddenham R, Eden JS, Gilbey T, Dwyer DE, Jennings Z, Holmes EC, et al. Human  
386 pegivirus in brain tissue of a patient with encephalitis. *Diagn Microbiol Infect Dis*. 2020;  
387 96: 114898. doi: 10.1016/j.diagmicrobio.2019.114898. PMID: 31753519.
- 388 27. Guo LY, Li YJ, Liu LL, Wu HL, Zhou JL, Zhang Y, et al. Detection of pediatric  
389 bacterial meningitis pathogens from cerebrospinal fluid by next-generation sequencing  
390 technology. *J Infect*. 2019; 78: 323-337. doi: 10.1016/j.jinf.2018.12.001. PMID:  
391 30550819.
- 392 28. Fan S, Qiao X, Liu L, Wu H, Zhou J, Sun R, et al. Next-generation sequencing of  
393 cerebrospinal fluid for the diagnosis of neurocysticercosis. *Front Neurol*. 2018; 9: 471.  
394 doi: 10.1016/j.clineuro.2020.105752. PMID: 29971042.
- 395 29. Fan S, Ren H, Wei Y, Mao C, Ma Z, Zhang L, et al. Next-generation sequencing of the  
396 cerebrospinal fluid in the diagnosis of neurobrucellosis. *Int J Infect Dis*. 2018; 67: 20-24.  
397 doi: 10.1016/j.ijid.2017.11.028. PMID: 29196276.
- 398 30. Tsai JD, Tsai HJ, Lin TH, Chang YY, Yang SH, Kuo HT. Comparison of the detection  
399 rates of RT-PCR and virus culture using a combination of specimens from multiple sites  
400 for enterovirus-associated encephalomyelitis during enterovirus 71 epidemic. *Jpn J Infect  
401 Dis*. 2014; 67: 333-338. doi: DOI 10.7883/yoken.67.333. PMID: 25241681.



- 402 31. Ooi MH, Solomon T, Podin Y, Mohan A, Akin W, Yusuf MA, et al. Evaluation of  
403 different clinical sample types in diagnosis of human enterovirus 71-associated hand-  
404 foot-and-mouth disease. *J Clin Microbiol.* 2007; 45: 1858-1866. doi:  
405 10.1128/JCM.01394-06. PMID: 17446325.
- 406 32. Perez-Velez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA, Pallansch MA,  
407 et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. *Clin*  
408 *Infect Dis.* 2007; 45: 950-957. Epub 2007/09/21. doi: 10.1086/521895. PMID:  
409 17879907.
- 410 33. Dube M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal  
411 transport enables neuron-to-neuron propagation of human coronavirus OC43. *J Virol.*  
412 2018; 92: e00404-18. doi: 10.1128/JVI.00404-18. PMID: 29925652.
- 413 34. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory  
414 coronaviruses. *J Virol.* 2000; 74: 8913-8921. Epub 2000/09/12. doi:  
415 10.1128/jvi.74.19.8913-8921.2000. PMID: 10982334.
- 416 35. Li YY, Li HP, Fan RY, Wen B, Zhang J, Cao XY, et al. Coronavirus infections in the  
417 central nervous system and respiratory tract show distinct features in hospitalized  
418 children. *Intervirology.* 2016; 59: 163-169. doi: 10.1159/000453066. PMID: 28103598.
- 419 36. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the  
420 central nervous system of a child with acute disseminated encephalomyelitis. *Pediatrics.*  
421 2004; 113: e73-76. doi: 10.1542/peds.113.1.e73. PMID: 14702500.

- 422 37. Jacomy H, St-Jean JR, Brison E, Marceau G, Desforges M, Talbot PJ. Mutations in the  
423 spike glycoprotein of human coronavirus OC43 modulate disease in BALB/c mice from  
424 encephalitis to flaccid paralysis and demyelination. *J Neurovirol.* 2010; 16: 279-293. doi:  
425 10.3109/13550284.2010.497806. PMID: 20642316.
- 426 38. Desforges M, Le Coupanec A, Dubeau P, Bourgoïn A, Lajoie L, Dube M, et al. Human  
427 coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of  
428 the central nervous system? *Viruses.* 2019; 12: 14. doi: 10.3390/v12010014. PMID:  
429 31861926;.
- 430 39. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The  
431 emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory  
432 findings. *Brain.* 2020; 143: 3104-3120. doi: 10.1093/brain/awaa240. PMID: 32637987.
- 433 40. Lindan CE, Mankad K, Ram D, Kociolek LK, Silvera VM, Boddaert N, et al.  
434 Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational,  
435 multicentre collaborative study. *Lancet Child Adolesc Health.* 2020; 5: 167-177. doi:  
436 10.1016/S2352-4642(20)30362-X. PMID: 33338439.
- 437 41. Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterle H, et al. Neurologic and  
438 neuroimaging findings in patients with COVID-19: A retrospective multicenter study.  
439 *Neurology.* 2020; 95: e1868-e82. doi: 10.1212/WNL.0000000000010112. PMID:  
440 32680942.

- 441 42. Almqvist J, Granberg T, Tzortzakakis A, Klironomos S, Kollia E, Ohberg C, et al.  
442 Neurological manifestations of coronavirus infections - a systematic review. *Ann Clin*  
443 *Transl Neurol.* 2020; 7: 2057-2071. doi: 10.1002/acn3.51166. PMID: 32853453.
- 444 43. Granerod J, Cunningham R, Zuckerman M, Mutton K, Davies NW, Walsh AL, et al.  
445 Causality in acute encephalitis: defining aetiologies. *Epidemiol Infect.* 2010; 138: 783-  
446 800. doi: 10.1017/S0950268810000725. PMID: 20388231.
- 447 44. Harvala H, McIntyre CL, McLeish NJ, Kondracka J, Palmer J, Molyneaux P, et al. High  
448 detection frequency and viral loads of human rhinovirus species A to C in fecal samples;  
449 diagnostic and clinical implications. *J Med Virol.* 2012; 84: 536-542. doi:  
450 10.1002/jmv.23203. PMID: 22246843.
- 451 45. Pelkonen T, Roine I, Anjos E, Kaijalainen S, Roivainen M, Peltola H, et al.  
452 Picornaviruses in cerebrospinal fluid of children with meningitis in Luanda, Angola. *J*  
453 *Med Virol.* 2012; 84: 1080-1083. doi: 10.1002/jmv.23304. PMID: 22585725.
- 454 46. Hazama K, Shiihara T, Tsukagoshi H, Matsushige T, Dowa Y, Watanabe M. Rhinovirus-  
455 associated acute encephalitis/encephalopathy and cerebellitis. *Brain Dev.* 2019; 41: 551-  
456 554. doi: 10.1016/j.braindev.2019.02.014. PMID: 30850156.
- 457 47. Blomqvist S, Savolainen C, Raman L, Roivainen M, Hovi T. Human rhinovirus 87 and  
458 enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. *J*  
459 *Clin Microbiol.* 2002; 40: 4218-4223. doi: 10.1128/jcm.40.11.4218-4223.2002. PMID:  
460 12409401.

- 461 48. Lauinger IL, Bible JM, Halligan EP, Aarons EJ, MacMahon E, Tong CY. Lineages, sub-  
462 lineages and variants of enterovirus 68 in recent outbreaks. *PLoS One*. 2012; 7: e36005.  
463 doi: 10.1371/journal.pone.0036005. PMID: 22536453.
- 464 49. Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated  
465 with influenza and other viral infections. *Acta Neurol Scand*. 2007; 115: 45-56. doi:  
466 10.1111/j.1600-0404.2007.00809.x. PMID: 17362276.
- 467 50. Mizuguchi M, Abe J, Mikkaichi K, Noma S, Yoshida K, Yamanaka T, et al. Acute  
468 necrotising encephalopathy of childhood: a new syndrome presenting with multifocal,  
469 symmetric brain lesions. *J Neurol Neurosurg Psychiatry*. 1995; 58: 555-561. doi:  
470 10.1136/jnnp.58.5.555. PMID: 7745402.
- 471 51. Britton PN, Dale RC, Blyth CC, Macartney K, Crawford NW, Marshall H, et al.  
472 Influenza-associated encephalitis/encephalopathy identified by the Australian Childhood  
473 Encephalitis study 2013-2015. *Pediatr Infect Dis J*. 2017; 36: 1021-1026. doi:  
474 10.1097/INF.0000000000001650. PMID: 28654561.
- 475 52. Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes.  
476 *Brain Dev*. 2009; 31: 521-528. doi: 10.1016/j.braindev.2009.02.012. PMID: 19339128.
- 477 53. Bohmwald K, Galvez NMS, Rios M, Kalergis AM. Neurologic alterations due to  
478 respiratory virus infections. *Front Cell Neurosci*. 2018; 12: 386. doi:  
479 10.3389/fncel.2018.00386. PMID: 30416428.

- 480 54. Granerod J, Ambrose HE, Davies NWS, Clewley JP, Walsh AL, Morgan D, et al. Causes  
481 of encephalitis and differences in their clinical presentations in England: a multicentre,  
482 population-based prospective study. *Lancet Infect Dis.* 2010; 10: 835-844. doi:  
483 10.1016/S1473-3099(10)70222-X. PMID: 20952256.
- 484 55. Li CX, Li W, Zhou J, Zhang B, Feng Y, Xu CP, et al. High resolution metagenomic  
485 characterization of complex infectomes in paediatric acute respiratory infection. *Sci Rep.*  
486 2020; 10: 3963. doi: 10.1038/s41598-020-60992-6. PMID: 32127629.
- 487 56. Fu LM, Niu BF, Zhu ZW, Wu ST, Li WZ. CD-HIT: accelerated for clustering the next-  
488 generation sequencing data. *Bioinformatics.* 2012; 28: 3150-3152. doi:  
489 10.1093/bioinformatics/bts565. PMID:23060610.
- 490 57. Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND.  
491 *Nat Methods.* 2015; 12: 59-60. doi: DOI 10.1038/nmeth.3176. PubMed PMID:  
492 25402007.
- 493 58. Li DH, Luo RB, Liu CM, Leung CM, Ting HF, Sadakane K, et al. MEGAHIT v1.0: A  
494 fast and scalable metagenome assembler driven by advanced methodologies and  
495 community practices. *Methods.* 2016; 102: 3-11. doi: 10.1016/j.ymeth.2016.02.020.  
496 PMID: 27012178.
- 497 59. Li DH, Liu CM, Luo RB, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node  
498 solution for large and complex metagenomics assembly via succinct de Bruijn graph.

- 499        Bioinformatics. 2015; 31: 1674-1676. doi: 10.1093/bioinformatics/btv033. PMID:  
500        25609793.
- 501    60. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu SN, Chitsaz F, Geer LY, et al.  
502        CDD: NCBI's conserved domain database. Nucleic Acids Res. 2015; 43: D222-D226.  
503        doi: 10.1093/nar/gku1221. PMID: 25414356.
- 504    61. Nakamura T, Yamada KD, Tomii K, Katoh K. Parallelization of MAFFT for large-scale  
505        multiple sequence alignments. Bioinformatics. 2018; 34: 2490-2492. doi:  
506        10.1093/bioinformatics/bty121. PMID: 29506019.
- 507    62. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New  
508        algorithms and methods to estimate maximum-likelihood phylogenies: assessing the  
509        performance of PhyML 3.0. Syst Biol. 2010; 59: 307-321. doi: 10.1093/sysbio/syq010.  
510        PMID:20525638.
- 511    63. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al.  
512        MetaPhlan2 for enhanced metagenomic taxonomic profiling. Nat Methods. 2015; 12:  
513        902-903. doi: 10.1038/nmeth.3589. PMID: 26418763.
- 514

515 **Figure legends**

516

517 **Fig. 1. Geographic context of the study.** (A) Maps showing the residential postal codes  
518 within Australia of patients with clinical diagnosis as encephalitis reported at the Children's  
519 Hospital at Westmead (CHW) between March 2014 and September 2016. Red star indicates  
520 one case and dark red star indicates two cases. (B) The bar chart showing the diversity of  
521 sample types collected in four states (NSW, QLD, VIC and WA) in Australia, coloured by  
522 sample types.

523

524 **Fig. 2. Diversity and abundance of viruses identified in this study.** The bar chart shows  
525 number of virus species in each sample: RNA viruses (blue) and DNA viruses (yellow). The  
526 heatmap shows the abundance level of different virus species within each library. The  
527 abundance level of reads was normalized to unique reads mapped per million input reads  
528 (RPM). HCoV-OC43, human coronavirus OC43; HCoV-HKU1, human coronavirus HKU1;  
529 HRV-A9, human rhinovirus A9; HRV-B52, human rhinovirus B52; Echo6, echovirus E6;  
530 HCoV-HKU1, human coronavirus HKU1; HPBV, human picobirnavirus; JCPyV, JC  
531 polyomavirus; WUPyV, WU polyomavirus.

532

533 **Fig. 3. Phylogenetic relationships and intra-specific diversity and of viruses identified by**  
534 **mNGS in this study.** Viruses identified as part of this project are marked in red and viruses  
535 from the same type/subgroup are shaded light red, whereas those representing background

536 phylogenetic diversity are shown in black. All horizontal branch lengths are scaled to the  
537 number of nucleotide substitutions per site, and trees are mid-point rooted for clarity.

538

539 **Fig. 4. Analysis of the novel picobirnavirus.** (A) Phylogenetic relationships of the RNA-  
540 dependent RNA polymerase (RdRp) proteins of the novel human picobirnavirus identified  
541 from this study and representative picobirnaviruses. (B) Genome organization of the novel  
542 human picobirnavirus from one stool sample. Segment 1 encodes two hypothetical proteins  
543 (ORF1 and ORF2), with arrows standing for directions of uncomplete ORFs. Segment 2  
544 encodes the viral RNA-dependent RNA polymerase (RdRp). The ribosome binding sites  
545 (RBS) and the ExxRxNxxxE amino acid (aa) motifs are marked.

546

547 **Fig. 5. Detailed analysis of the bacteria identified in this study.** (A) Bacterial taxa  
548 identified using mNGS. Each dot represents a taxonomic entity. From the inner to outer  
549 circles, the taxonomic levels range from kingdom to species. Different colored dots indicate  
550 different taxonomic levels according to the color key shown. Numbers in parentheses indicate  
551 the total number of unique taxonomies detected at each level. (B) Profiling the relative  
552 abundance of the bacteria identified here. Cladogram representing the predominant family  
553 and top 16 bacterial species present in these cases. Circle size depicts microbial abundance.  
554 Abundance levels (reads per million total reads) were estimated using MetaPhlAn2. The  
555 taxonomic tree was visualized using GraPhlAn.


556




557 **Fig. 6. Heatmap of the abundance level for the bacteria identified in each case studied**

558 **here.** The abundance level of microbial reads was normalized to RPM, and the estimation

559 was performed at the species level.




**Figure 1**



562 \*NPA:Nasopharygeal aspirates; CSF: Cerebrospinal fluid; SW: Swabs; ETA:Endotracheal aspirates


563 **Figure 2**

564



565


566 **Figure 3**



567

568 **Figure 4**





571

\*NPA:Nasopharygeal aspirates;

## Supporting Information Captions

**Fig S1. Summary of taxonomy and abundance from meta-transcriptomic sequencing of the libraries from each patient.** The bar chart shows the proportion of assigned taxa according to the keys provided. The panel shows the proportion of reads that were assigned as quality controlled (QC), human and non-human in each library.


**Fig S2. Logic model to determine potential the pathogenicity of the viruses, bacteria and fungi identified here.** #mNGS = metagenomic next-generation sequencing. \*Sterile sites included blood, serum, and CSF; non-sterile sites included nasopharyngeal aspirates, endotracheal samples, throat and nasal swabs, as well as stool and rectal swabs. Infectious and immune-mediated syndromes were defined by the advanced clinical expert panel.  
^Abundance was determined to be high if sequence reads were above 10000 RPM, or low if below 1000 RPM. In the event of detection in multiple samples sterile samples taken priority.

**Table S1.** Summary of laboratory tests performed on the encephalitis cases.


**Table S2.** Information on the RNA sequencing libraries generated in this study.

**Table S3.** Identity of viruses identified in this study with the most closely related sequence available on public sequence databases.





\*NPA:Nasopharyngeal aspirates; CSF: Cerebrospinal fluid; SW: Swabs; ETA:Endotracheal aspirates



**Table S1.** Summary of laboratory tests performed on the encephalitis cases.

Case No.	Infectious Disease														Immune Mediated					
	CSF Culture			CSF PCR									Serology					Sputum PCR	Gastro-Intestinal	
	<i>Bacterial</i>	<i>Fungal</i>	<i>Mycoplasma</i>	HSV	EV	HPeV	VZV	EBV	CMV	HHV	N. Meningitidis	M. pneumoniae	Acute EBV	M. pneumoniae IgM	Rotavirus	Adenovirus	Enterovirus		Bacterial Culture	CSF NDMA IgG
1	N			N	N												N			N
2				N	N						N									
3	N			N	N					N							N			N
4	N			N	N											N				
5	N			N	N								N	N			N			N
6	N	N	N	N	N								N	N					N	N
7	N	N	N	N	N	N		N			N	N								E
8	N	N	N	N	N		N	N	N				N	N					N	P
9	N	N	N	N	N															
10	N		N	N	N							N							N	N
11	N			N	N		N		N	N						N	N	N		
12	N			N	N							N								N
13	N			N	N	N	N	N		N			N			P		N	N	N
14	N			N	N		N													N
15	N			N	N	N	N	N	N	N	N		N				N			
16	N			N	N	N	N		N	N			N				N			
17													N			N	N			
18				N	N		N				N	N	N	N					N	

N = Negative, P = Positive, E = Equivocal, Blank = Untested. HSV = Herpes Simplex Virus, EV = Enterovirus, HPeV = Human Parechovirus, VZV = Varicella Zoster Virus, EBV = Epstein-Barr Virus, CMV = Cytomegalovirus, HHV = Human Herpesvirus. Negative for acute EBV = No EBV IgM, and/or pos EBV NA IgG. \* Rhinovirus, # Coronavirus, \*\* Stool tested >day 7 of admission, no diarrhoea. Oligoclonal banding is positive if present only in CSF or is higher in CSF than in serum.

**Table S2.** Information on the RNA sequencing libraries generated in this study.

Case No.	Libraries	Sample types	Paired reads (150bp)	Data	QC	Total human	Total non-human
<b>01</b>	14618NPA	NPA	68,331,435	20.64 Gb	20.95%	38.68%	40.37%
	1469	Serum	62,439,715	18.86 Gb	32.38%	65.91%	1.71%
	14617	Stool	72,597,211	21.92 Gb	45.14%	0.42%	54.43%
	14619	Stool	76,093,344	22.98 Gb	35.56%	0.37%	64.07%
	14618S	Stool	81,029,503	24.47 Gb	45.94%	3.32%	50.74%
<b>02</b>	14918	NPA	69,918,956	21.12 Gb	32.94%	7.13%	59.93%
<b>03</b>	16118	NPA	64,014,451	19.33 Gb	37.97%	9.36%	52.67%
<b>04</b>	1972	CSF	55,650,564	16.81 Gb	16.53%	41.33%	42.14%
	19718	NPA	61,763,723	18.65 Gb	30.09%	49.55%	20.36%
<b>05</b>	2051	CSF	12,207,214	3.69 Gb	26.55%	13.48%	59.98%
	2052	CSF	65,679,279	19.84 Gb	17.69%	40.40%	41.91%
	2053	CSF	45,372,654	13.70 Gb	33.33%	5.92%	60.75%
<b>06</b>	4	Blood	80,788,125	24.40 Gb	37.62%	61.03%	1.35%
	419	Urine	65,728,328	19.85 Gb	19.32%	11.88%	68.80%
	420	Urine	59,130,993	17.86 Gb	15.69%	9.48%	74.84%
<b>07</b>	1419	NPA	70,769,034	21.37 Gb	51.54%	0.41%	48.05%
<b>08</b>	6019	Urine	63,645,388	19.22 Gb	14.21%	5.60%	80.19%
	6020	Urine	66,076,819	19.96 Gb	14.36%	6.46%	79.18%
	631	CSF	64,218,139	19.39 Gb	24.16%	12.35%	63.49%
<b>09</b>	83	Blood	76,472,229	23.09 Gb	33.29%	65.60%	1.10%
<b>10</b>	4819	Urine	69,409,747	20.96 Gb	22.08%	6.58%	71.34%
	481	CSF	63,814,144	19.27 Gb	20.83%	28.25%	50.91%
<b>11</b>	4818	NPA	70,749,343	21.37 Gb	39.21%	17.34%	43.45%
	4817	Stool	69,714,937	21.05 Gb	41.82%	0.62%	57.56%
<b>12</b>	561	CSF	61,044,714	18.44 Gb	24.18%	11.16%	64.66%
<b>13</b>	951	CSF	30,481,591	9.21 Gb	25.17%	9.84%	64.99%
	9518	Respiratory Swab	62,643,416	18.92 Gb	17.66%	52.71%	29.64%
<b>14</b>	1031	CSF	60,509,053	18.27 Gb	31.36%	19.83%	48.81%
	10318	Respiratory Swab	71,156,865	21.49 Gb	27.28%	2.80%	69.92%
<b>15</b>	31	CSF	59,215,458	17.88 Gb	29.78%	26.16%	44.05%
	317	Rectal Swab	74,947,448	22.63 Gb	30.98%	0.31%	68.70%
	318	Throat Swab	72,626,978	21.93 Gb	29.09%	2.49%	68.41%
	003X	Urine	56,431,288	17.04 Gb	16.60%	11.15%	72.25%
<b>16</b>	881	CSF	52,399,272	15.82 Gb	27.15%	21.51%	51.34%
	8818	NPA	62,379,902	18.84 Gb	31.18%	6.98%	61.84%
	8817	Rectal Swab	71,705,712	21.66 Gb	21.80%	38.09%	40.11%
<b>17</b>	26619	NPA	66,107,489	19.96 Gb	17.72%	56.84%	25.45%
	26617	Rectal Swab	79,261,749	23.94 Gb	37.49%	9.57%	52.94%
	26618R	Respiratory Swab	69,315,594	20.93 Gb	24.91%	10.32%	64.77%
	26618S	Stool	61,180,294	18.48 Gb	28.56%	6.52%	64.92%
<b>18</b>	65419	ETA	66,718,955	20.15 Gb	16.71%	68.52%	14.77%
	65417	Rectal Swab	69,257,149	20.92 Gb	26.66%	0.68%	72.66%
	65418	Throat Swab	67,246,928	20.31 Gb	24.50%	3.82%	71.69%
<b>Total</b>			2,770,245,130	836.61 Gb			

**Table S3.** Identity of viruses identified in this study with the most closely related sequence available on public sequence databases.

Virus	Closest relative	Identity	Genes or genome alignments used in the phylogenetic analysis	
			Domain	Alignment length (bp)
HCoV-OC43/03-16118/NSW/AU/2019	MK303622/HCoV-OC43/MDS11	99.73%	Spike protein	4433
HCoV-OC43/09-83/QLD/AU/2019	MK303622/HCoV-OC43/MDS11	99.73%	Spike protein	4433
HCoV-OC43/15-318/WA/AU/2019	MK303622/HCoV-OC43/MDS11	99.65%	Spike protein	4433
HCoV-HKU1/17-26618/WA/AU/2019	MH940245/HCoV-HKU1/SI17244	99.75%	Partial Spike protein	2446
HCoV-HKU1/17-26617/WA/AU/2019	MH940245/HCoV-HKU1/SI17244	99.75%	Partial Spike protein	2446
HRV-A9/01-14618/NSW/AU/2019	FJ445114/HRV-A9/F01	96.48%	Near complete genome	6808
HRV-B52/11-4818/VIC/AU/2019	FJ445137/HRV-B52/F10	92.82%	Near complete genome	6513
HRV-B52/11-4817/VIC/AU/2019	FJ445137/HRV-B52/F10	92.82%	Near complete genome	6513
HPBV/17-26618/WA/AU/2019	AVD54068/Macaque PBV 33	72.44%(aa)	RdRp	524 amino acids
JC-PyV/10-4819/QLD/AU/2019	AF015533/JC-PyV/227	99.79%	Partial genome	2378
WU-PyV/03-16118/NSW/AU/2019	GU296361/WU-PyV/O140	99.82%	Near complete genome	5230